

Supplemental Information


**Commitment and oncogene-induced
plasticity of human stem cell-derived
pancreatic acinar and ductal organoids**

Ling Huang, Ridhdi Desai, Daniel N. Conrad, Nayara C. Leite, Dipika Akshinthala, Christine Maria Lim, Raul Gonzalez, Lakshmi B. Muthuswamy, Zev Gartner, and Senthil K. Muthuswamy

A

	iPS11	iPS13
Donor Age	26	27
Donor Gender	Male	Female
Donor weight (lbs)	215	106
Donor BMI (CDC calculator)	32.7	21.4
Donor Race		
Health Information	Healthy	Healthy
Tissues used for generating iPS cells	Eritroblasts	Eritroblasts
Passages used for experiments	9	18

B



C






Figure S1. Induction of duct-like and acini-like organoids using progenitors derived from iPS cells (related to Figure 1) (A) Donor information for iPS cell lines used. (B) Phase contrast images of duct-like (DU, blue) and acini-like (AC, orange) organoids using iPSC-derived pancreatic progenitors. Scale bar, 50 μm . (C) Quantification of organoid sizes (N = minimal 200). Whisker-box plot, range 5-95%; center lines indicate median values; grey dots represent individual measurements. ***, $p < 0.001$. Results were summary from three independent cultures.

A


	Gene Expression (arbitrary unit, x10 ⁻³)		
	PP	DU	AC
PDX1	29.72	78.85	106.52
SOX9	25.97	229.48	4.66
HNF1B	141.21	175.75	84.28
HNF1A	21.85	57.07	15.53
RBPJL	4.12	12.68	12.20
RBPJ	630.67	1742.17	639.18
CPA2	2.62	6.34	4.66
CEL	6.12	6.34	15.31
PNLIP	1.75	0.00	18.42
CTRB1	0.00	0.00	3.88
CTRC	2.62	0.00	4.66

B


CALN1
Patient ID: 2032
Tissue: normal pancreas
Antibody: HPA036278

C


GRID2
Patient ID: 2162
Tissue: normal pancreas
Antibody: HPA056253

D


DLG2
Patient ID: 2220
Tissue: normal pancreas
Antibody: HPA021307

E


LRP1B
Patient ID: 4156
Tissue: normal pancreas
Antibody: HPA069094

F


SLC4A4
Patient ID: 2940
Tissue: normal pancreas
Antibody: HPA035628

G

ANXA4
Patient ID: 2032
Tissue: normal pancreas
Antibody: CAB005076

H

C8orf34
Patient ID: 2162
Tissue: normal pancreas
Antibody: HPA044420

I

MAG1
Patient ID: 2032
Tissue: normal pancreas
Antibody: HPA031853

Figure S2. Single nuclei RNA sequencing detects expression of pancreatic differentiation markers in organoids (related to Figure 2) (A) Expression of classical pancreatic lineage markers in different cell groups. Results were obtained from two independent organoid cultures and separate sequencing. (B-E) Expression of acini-like organoid-enriched markers in normal human pancreas. Images obtained from Human Protein Atlas. (F-I) Expression of duct-like organoid-enriched markers in normal human pancreas. Images obtained from Human Protein Atlas.




Figure S3. Expression of Pancreatic lineage markers during organoid morphogenesis (related to Figure 3) (A) Pancreatic lineage marker expression in organoids induced from iPSC-derived pancreatic progenitors. Results from one batch of organoid culture. (B) *PDX1* RNA levels were quantitated by quantitative PCR. Floating column charts represent RNA measurements from quantitative PCR (N=3, independent cultures); Hinges represent maximal and minimal values, central lines indicate mean values; dots represent individual measurements.




Figure S4. Effects of wildtype and mutant GNAS on organoid differentiation (related to Figure 4) (A) Expression of MUC2 and E-cadherin in duct-like and acini-like organoids with and without expressing wildtype GNAS (N=3, independent cultures). MUC2, red; E-cadherin, green; DAPI, blue. Scale bar, 100 μ m. (B) Expression of MUC2 and E-cadherin in acini-like organoids with and without expressing GNAS^{R201C} (N=3). MUC2, red; E-cadherin, green; DAPI, blue. Scale bar, 100 μ m. (C) Quantification of MUC2 and MUC5AC expression in acini-like organoids with and without expressing GNAS^{R201C} (N=3). (D) CFTR RNA expression in organoids with GNAS^{R201C}. N= 2, biological repeats. (E-F) Normal (top panels) and abnormal (bottom panels) mouse pancreatic tissues with (hematoxylin and eosin stained) at eight weeks (D) (N=8) and 14 weeks (E) (N=4) post transplantation with duct-like organoids expressing GNAS^{R201C}. Scale bars, 100 μ m.




Figure S5. Effects of $KRAS^{G12D}$ expression on organoids (related to Figure 5) (A) Expression of $KRAS$ in the pancreas of healthy subjects and PDAC patients. Data obtained from The Cancer Genome Atlas. (B-C) Immunoblot analysis for $KRAS$ and ERK phosphorylation in duct-like (B) and acini-like (C) organoids. Numbers blots represent normalized intensities of protein bands. (D) Phase contrast images of duct-like organoids expressing high levels of $KRAS^{G12D}$ (top panel) and organoids without $KRAS^{G12D}$ expression (bottom panel). (E) Pseudocolor images indicating p16^{INK4A} intensities in organoids without (top panel) and with (bottom panel) $KRAS^{G12D}$ expression. Images converted from immunofluorescent staining of p16^{INK4A}. Scale bars, 100 μ m. (F) Quantification of p16^{INK4A} expression per nuclei in organoids without and with $KRAS^{G12D}$ expression (N>2500, from three independent cultures). Y-axis present signals normalized to maximal values of 8 bit image (255). Whisker-box plot, range 5-95%; center lines indicate median values; grey dots represent individual measurements. ***, p<0.001.




Figure S6. TGFβ treatments induce biological changes in organoids (related to Figure 6)
(A) Phase contrast images of duct-like and acini-like organoids without and with TGFβ treatments. Scale bar, 50 μm. **(B)** Pseudocolor images indicating p16^{INK4A} intensities in *KRAS*^{G12D} expressing organoids with TGFβ treatments. Images converted from immunofluorescent staining of p16^{INK4A}. Scale bars, 100 μm. **(C)** Quantification of p16^{INK4A} expression per nuclei in *KRAS*^{G12D} organoids with TGFβ treatments (N>2500, from three independent cultures). Y-axis present signals normalized to maximal values of 8 bit image (255). Whisker-box plot, range 5-95%; center lines indicate median values; grey dots represent individual measurements. ***, p<0.001.




Figure S7. Orthotopic transplantation of organoids into mice (related to Figure 7) (A) H&E images of mouse pancreas transplanted with duct-like (DU) and acini-like organoids (AC) without oncogene expression (N=10 mice for each group). Scale bars, 100 μ m. (B) Mouse pancreatic tissues adjacent to organoid-derived lesions exhibiting pancreatitis-like histology. Scale bars, 100 μ m. (C-D) Protein expression in lesions grown from *KRAS*^{G12D} expressing duct-like (C) (N=9 mice) and acini-like (D) (N=10 mice) organoids. KRT19, red; Ki67, green; KRT7, teal; MUC5AC, yellow; SOX9, purple. Scale bars, 100 μ m. (E-F) Protein expression in human PDAC tumor tissues. Left panel: E-cadherin, green; MUC2, red; DPAI, blue. Right panel: KRT7, green; MUC5AC, red.